Harshfine Chemopharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 26-06-2024
- Paid Up Capital ₹ 0.10 M
as on 26-06-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.35 Cr
as on 26-06-2024
- Revenue -21.71%
(FY 2022)
- Profit -574.94%
(FY 2022)
- Ebitda -177.76%
(FY 2022)
- Net Worth -186.40%
(FY 2022)
- Total Assets 15.28%
(FY 2022)
About Harshfine Chemopharma
The Corporate was formerly known as Harsh Finechemicals Industries Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.35 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Hanisha Chander, Anupama Bhatnagar, and Ashwin Vira serve as directors at the Company.
- CIN/LLPIN
U24100MH2011PTC217168
- Company No.
217168
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Harshfine Chemopharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hanisha Chander  | Director | 04-Jun-2019 | Current |
| Anupama Bhatnagar | Director | 27-Feb-2019 | Current |
| Ashwin Vira | Director | 29-Apr-2017 | Current |
Financial Performance of Harshfine Chemopharma.
Harshfine Chemopharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.71% decrease. The company also saw a substantial fall in profitability, with a 574.94% decrease in profit. The company's net worth observed a substantial decline by a decrease of 186.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harshfine Chemopharma?
In 2020, Harshfine Chemopharma had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tjsb Sahakari Bank Limited Creation Date: 05 Oct 2015 | ₹1.35 Cr | Satisfied |
How Many Employees Work at Harshfine Chemopharma?
Harshfine Chemopharma has a workforce of 6 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harshfine Chemopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harshfine Chemopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
